Cochrane · systematic review · CD007795
Vaccination for preventing postherpetic neuralgia
Chen, N, Li, Q, Zhang, Y, et al. · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 25%High 3 · 75%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Vaccination compared with placebo for preventing postherpetic neuralgia
Population: people at risk for postherpetic neuralgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Persistence of PHN among all subjects a numerical rating scale for pain1 Vaccination vs placebo | RR 0.31 [0.18, 0.54] | 1 study · 38501 participants | High |
Persistence of PHN among subjects developing herpes zoster a numerical rating scale for pain1 Vaccination vs placebo | RR 0.64 [0.38, 1.09] | 1 study · 957 participants | Moderate |
Deaths among all subjects during the whole study clinical Vaccination vs placebo | RR 1 [0.91, 1.1] | 1 study · 38546 participants | High |
Serious adverse events among subjects in the adverse event substudy clinical manifestations Vaccination vs placebo | RR 1.53 [1.03, 2.25] | 1 study · 6616 participants | High |